Market News

UGP vs. ENB: Which Stock Is the Better Value Option?

APA vs. LNG: Which Stock Is the Better Value Option?

AER vs. WAB: Which Stock Is the Better Value Option?

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

SGI vs. HD: Which Stock Is the Better Value Option?

UMC vs. NVMI: Which Stock Is the Better Value Option?

MKSI vs. ROK: Which Stock Is the Better Value Option?

GIC vs. GWW: Which Stock Is the Better Value Option?

Navient's restructuring sparks S&P liquidity and funding concerns, prompting a negative outlook despite unchanged credit ratings.

Players: Pfizer, Novartis, Bayer, Astellas and Sarepta. Profile: next-gen AAV delivery, including engineered capsids, targeting, safety and scalable m...

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call October 30, 2026 8:30 AM EDTCompany ParticipantsRyan Crowe - Senior Vice President of Inv...

Intel stock plummets after the chip maker issued underwhelming earnings guidance.

Boost ROI via regional capacity, precision and titanium fasteners, partnerships, tiered pricing, and a focus on medical devices, pins and inserts.Dubl...

Exelon Corporation (EXC) Q3 2026 Earnings Call October 30, 2026 10:00 AM EDTCompany ParticipantsRyan Brown - Vice President of Investor RelationsCalvi...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. Conestoga...

Healthcare Realty Trust Incorporated (HR) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDTCompany ParticipantsDoris Lo - First Vice President of Cor...

There was a lot to like about the company's recent quarter, but liquidity remains a pressing issue.

Hamilton Insurance Group, Ltd. (HG) Q3 2026 Earnings Call October 30, 2026 9:30 AM EDTCompany ParticipantsDarian Niforatos - VP & Head of Investor...

Forum Energy Technologies, Inc. (FET) Q3 2026 Earnings Call October 30, 2026 11:00 AM EDTCompany ParticipantsRob Kukla - Director of Investor Relation...

Boost ROI via targeted siRNA delivery, personalized therapies, pipeline-expanding acquisitions, and focus on renal, rare, neurological and oncology in...